Ainos, Inc. (AIMD) 

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.

Show less

Over the last 12 months, insiders at Ainos, Inc. have bought $0 and sold $0 worth of Ainos, Inc. stock.

On average, over the past 5 years, insiders at Ainos, Inc. have bought $531,378 and sold $300,000 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 61,157 shares for transaction amount of $48,559 was made by lee ting-chuan (director) on 2023‑04‑26.